Advances in the Pharmacology of Neuroendocrine Tumors
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 982
Special Issue Editor
Special Issue Information
Dear Colleagues,
Neuroendocrine tumors of the gastrointestinal tract and pancreas are a heterogenous group of tumors with growing incidence and prevalence but still challenging to diagnose, follow up, and treat. Due to their potential to secrete various hormones, growth factors, and vasoactive substances, which add to the versatility of clinical presentation, they are attractive to experts of different specialties, including gastroenterologists, endocrinologists, oncologists, cardiologists, surgeons, pathologists, specialists in nuclear medicine just being some of the mentioned. Great advances have been made in the field of pharmacology and treatment options following the PROMID study, which led the way into the treatment of nonfunctional advanced neuroendocrine tumors. Since then, different agents and protocols have been introduced, which not only improved quality of life but also life expectancy. Moreover, efforts have been put into recognizing early tumor markers influencing prognosis and outcomes, as well as an understanding of molecular pathways driving tumor development which serve as potential treatment targets tailored to personalized patient needs. In this Special Issue, we would like to invite all with expertise in the treatment of patients with different types and stages of gastroenteropancreatic neuroendocrine tumors to share their research on the topic and add additional knowledge to aid disease treatment.
Dr. Maja Cigrovski Berković
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic neuroendocrine tumors
- gastrointestinal endocrine tumors
- treatment
- systemic therapy
- somatostatin
- interferon-alpha
- molecular-targeted agents
- tumor apoptosis
- symptom control
